Sale on Ophthalmic Equipment - Starting from 16 November!
Empatica launches WellPD, an FDA-cleared and CE-marked Parkinson’s wearable that monitors motor symptoms, sleep and activity at home, providing daily insights for patients and care teams.
Empatica has introduced the WellPD Parkinson’s wearable, an FDA-cleared, CE-marked monitoring system for home use. The wrist-worn device works with a smartphone app to track motor symptoms, sleep, and physical activity, giving patients information about changes in their condition.
The system is available to order in several markets, including the US, Canada, Australia and multiple European countries. Empatica's official website also confirms availability in the UK and New Zealand.
WellPD Parkinson’s Wearable Tracks Motor Symptoms
The WellPD Parkinson’s wearable uses sensors and clinically validated algorithms to measure movement and physiological signals throughout the day.
Its monitoring capabilities include:
Bradykinesia, or slow movement
Dyskinesia, involving involuntary movements
Tremor and changes in movement patterns
Sleep and daily physical activity
The companion app converts these measurements into daily summaries, letting users review symptom patterns over time.
Patients can also record medication schedules and compare them with changes in movement, activity and sleep. This helps capture information that may be difficult to remember during medical appointments.
Parkinson’s symptoms can vary during the day, particularly as medication effects change. These fluctuations may not be apparent during a scheduled clinical consultation.
WellPD provides additional information that patients can share with caregivers and healthcare professionals. Its summaries may help clinicians understand symptom patterns between appointments and assess reported changes.
The system supports ongoing monitoring rather than replacing clinical assessments or treatment decisions.
Empatica CEO and co-founder Matteo Lai said: “Empatica was founded on the belief that technology should be friendly, caring, and more human.”
He explained that the company aims to make its wearable monitoring technology accessible to patients and families in their homes.
The US Food and Drug Administration granted 510(k) clearance to Empatica's Health Monitoring Platform for Parkinson's in August 2026. The platform also holds certification under the European Union's Medical Device Regulation.
These regulatory milestones support WellPD's commercial introduction for Parkinson's monitoring.
Empatica has developed other remote monitoring technologies for neurological conditions, including epilepsy. Its Parkinson's platform extends that work into movement disorder monitoring.
Empatica+1
WellPD incorporates technology from Empatica's 2025 acquisition of PKG Health.
PKG developed algorithms for assessing Parkinson's motor symptoms through wearable monitoring. Empatica has combined those capabilities with its existing medical wearable technology.
According to the company, more than 70 peer-reviewed publications support the underlying algorithms, and they are used across more than 150 hospitals and clinical centres worldwide.
The technology also supports research into disease progression, therapy response and digital measurements used in clinical trials.
WellPD extends Empatica's remote monitoring portfolio from clinical and research applications to patient-managed symptom tracking.
Its combination of continuous measurements, medication records and daily summaries provides a way to document symptoms outside healthcare facilities.
For medical technology professionals, the launch adds another regulated wearable system to the growing field of neurological monitoring. Coverage on Medigear.uk follows developments in wearable medical devices and remote patient monitoring technologies.
Source: Medical Device Network
Tell us the model and destination — our sourcing team will respond within one business day.

The Zimmer Monogram robot is now with US regulators. Zimmer Biomet has filed a 510(k) submission for…

The Abbott Encantor trial has begun. Abbott said on Thursday that it has started the VOYAGER CE clin…

Johnson & Johnson (J&J) said on Thursday that a Houston hospital will be the first to instal…
Approvals, trials, recalls and market moves — the essentials for procurement and clinical teams.